Valentine Jehl

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: March 19, 2025

Long-Term Safety Evaluations in the Presence of Switching: Evaluation of Two Approaches.

Long-Term Safety Evaluations in the Presence of Switching: Evaluation of Two Approaches.

Journal: Pharmaceutical statistics

Published: December 05, 2024

Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project.

Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project.

Journal: Drug safety

Published: November 15, 2023

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting.

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting.

Journal: Ophthalmology science

Published: January 30, 2023

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 01, 2022

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.

Journal: The British journal of dermatology

Published: April 06, 2021

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.

Journal: Trials

Published: September 08, 2020

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study.

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: November 19, 2019

Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.

Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: August 09, 2018

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 29, 2016

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 26, 2013

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

Journal: Cancer research

Published: February 26, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026